Johnson & Johnson (NYSE:JNJ) Shares Sold by Criterion Capital Advisors LLC

Criterion Capital Advisors LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 15.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,417 shares of the company’s stock after selling 255 shares during the period. Criterion Capital Advisors LLC’s holdings in Johnson & Johnson were worth $224,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in JNJ. Gallagher Fiduciary Advisors LLC grew its position in Johnson & Johnson by 18.9% in the third quarter. Gallagher Fiduciary Advisors LLC now owns 2,577 shares of the company’s stock worth $401,000 after buying an additional 409 shares during the last quarter. Axxcess Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 71.8% in the 3rd quarter. Axxcess Wealth Management LLC now owns 66,481 shares of the company’s stock worth $10,354,000 after acquiring an additional 27,795 shares during the last quarter. Augustine Asset Management Inc. raised its position in shares of Johnson & Johnson by 7.6% during the third quarter. Augustine Asset Management Inc. now owns 3,815 shares of the company’s stock worth $594,000 after purchasing an additional 269 shares during the period. Alerus Financial NA lifted its holdings in shares of Johnson & Johnson by 1.7% during the third quarter. Alerus Financial NA now owns 4,299 shares of the company’s stock valued at $670,000 after purchasing an additional 71 shares during the last quarter. Finally, Elevatus Welath Management boosted its position in shares of Johnson & Johnson by 29.1% in the 3rd quarter. Elevatus Welath Management now owns 1,802 shares of the company’s stock valued at $281,000 after purchasing an additional 406 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on JNJ. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Thursday, June 20th. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price target for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. The Goldman Sachs Group began coverage on shares of Johnson & Johnson in a research note on Thursday, May 30th. They set a “neutral” rating and a $160.00 target price on the stock. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Sunday. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research report on Monday, June 17th. Eight analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $174.07.

Johnson & Johnson Trading Up 0.2 %

NYSE:JNJ opened at $146.16 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The company has a market capitalization of $351.76 billion, a P/E ratio of 9.11, a P/E/G ratio of 2.43 and a beta of 0.53. The stock’s 50 day moving average price is $148.14 and its 200 day moving average price is $154.06. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. Johnson & Johnson’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.68 EPS. On average, research analysts forecast that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were issued a dividend of $1.24 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.39%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.